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Psoriasis is a chronic skin disease with an immuno-
cytic in®ltrate, including activated T lymphocytes,
producing multiple cytokines that can in¯uence the
phenotype of epidermal keratinocytes. In these stu-
dies we examined the effect of the cytokines inter-
feron-g and interleukin-13 or interleukin-4 on
keratinocytes, alone and in combination, on surface
levels of HLA-DR, intercellular adhesion molecule 1,
and CDw60, as well as the transcription factors
STAT1, STAT6, and BCL-6. As CDw60 is an acety-
lated form of the GD3 ganglioside and may function
as a T cell costimulatory molecule, the modulation
of CDw60 expression by keratinocytes in psoriatic
lesions was highlighted to gain insight into poten-
tially important T cell-keratinocyte interactions.
Interferon-g was observed to block the interleukin-4-
or interleukin-13-mediated induction of CDw60 on
cultured keratinocytes, but not induction of the tran-
scription factor STAT6. Interleukin-13 and interleu-
kin-4 were unable to block interferon-g-mediated
induction of STAT1 or BCL-6, however, or the
upregulation of intercellular adhesion molecule 1 and
HLA-DR. In psoriatic plaques, CDw60 was not con-
sistently detected on keratinocytes in acute lesions,
but was detected predominantly on basal layer kera-
tinocytes in chronic lesions. In addition we found
that BCL-6 levels were increased in psoriatic lesions;
in acute lesions BCL-6 was primarily localized in the
basal layer keratinocytes, whereas in chronic plaques
nuclear BCL-6 was predominantly expressed by ker-
atinocytes in the suprabasal cell layers. These studies
highlight the complex modulation of the keratino-
cyte phenotype by immunocyte-derived cytokines,
in which induction of CDw60 involving interleukin-
4, or interleukin-13 was antagonized by interferon-g.
We suggest in psoriatic plaques that the presence or
absence of CDw60 expression by keratinocytes may
re¯ect the dynamic interplay between Th-1-type
cytokines such as interferon-g and Th-2-type cyto-
kines such as interleukin-4 and interleukin-13. The
ability of interferon-g to induce the transcription
repressor BCL-6 may also contribute to the overall
immunologic events in skin, including suppression of
the intermediates in the synthetic pathway leading to
expression of the T cell costimulatory ganglioside
CDw60. Key words: BCL-6/ganglioside/immunocyte/
STAT1/STAT6. J Invest Dermatol 116:305±312, 2001
P
soriasis is a chronic in¯ammatory skin disease (Valdi-
marsson et al, 1986; Gottlieb et al, 1995; Bos and DeRie,
1999) characterized by hyperproliferation of basal and
suprabasal keratinocytes. The biochemical mechanism
or mediators responsible for this hyperproliferation
remains unclear, but immunocytes and cytokines have long been
suspected of playing a pathogenic role (Nickoloff, 1999). This
hypothesis is supported by the ®ndings that a T cell in®ltrate and
cytokines, such as interferon-g (IFN-g), can be identi®ed in
psoriatic lesions, and that these factors can induce expression of a
variety of cell surface activation molecules associated with psoriasis
(Fierlbeck et al, 1990; Barker et al, 1993). In chronic psoriatic
lesions, many immunologically relevant proteins such as inter-
cellular adhesion molecule 1 (ICAM-1), major histocompatibility
class I (MHC class I) and MHC class II antigens, as well as
carbohydrate-bearing molecules such as the acetylated GD3 gang-
lioside CDw60, have been shown to be upregulated on the surface
of lesional keratinocytes (Cooper, 1992; Skov et al, 1997). The
signaling pathways responsible for the modulation of these
important cell surface molecules on keratinocytes is poorly
understood, however, in psoriasis. Moreover, although the
synthetic pathway leading to the synthesis and expression of
gangliosides such as GD3 has been established for keratinocytes,
exactly which transcriptional factors contribute to CDw60 has not
been elucidated (Paller et al, 1993, 1995).
Recently, our group has shown that a pathogenic T cell line,
which is CD161 positive, can induce an acute psoriatic lesion when
injected into symptomless autologous human skin engrafted onto a
severe combined immunode®ciency (SCID) mouse (Nickoloff et al,
2000). Further characterization of this T cell line revealed that it
produced both Th-1 (IFN-g) and Th-2 [interleukin-13 (IL-13)]
cytokines upon stimulation in vitro. RNase protection assays in an
acute psoriatic lesion produced after in vivo injection, however,
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demonstrated that there was a cytokine switch to a predominantly
Th-1 IFN-g pro®le, with only barely detectable levels of IL-13 and
IL-4 mRNA. Interestingly, this correlates with an absence of
CDw60 expression in keratinocytes in this acute lesion. Whether
an imbalance of Th-1 versus Th-2 cytokines has an effect on the
pattern of activation of keratinocytes may be pertinent to the
pathogenesis of psoriasis (Nickoloff, 1991; Gottlieb, 1994;Schlaak
et al, 1994).
IFN-g and IL-13 are cytokines that have demonstrated opposing
functions in human monocytes (Dickensheets and Donnelly, 1999).
It is known that IFN-g is a potent inducer of the transcription of many
genes involved in in¯ammatory reactions. Genes that are upregulated
by IFN-g include both MHC class I and class II molecules, in addition
to adhesion molecules such as ICAM-1 (Tessitore et al, 1998;
Piskurich et al, 1999). It has also been previously demonstrated that
CDw60 expression is not upregulated by treatment with IFN-g, but is
induced when cultured keratinocytes are exposed to IL-13 (Skov et al,
1997). In chronic psoriatic lesions, CDw60 expression has been
localized to the basal and suprabasal keratinocytes, although
considerable variation in the pattern of expression was observed in
12 different plaques (Skov et al, 1997). This acetylated ganglioside
CDw60 is also an activation marker for both T and B lymphocytes
(Vater et al, 1997). A very high frequency of CDw60 positive T cells is
found in the synovial ¯uid of normal and arthritic patients and in
cutaneous psoriatic lesions (Baadsgaard et al, 1990; Fox et al, 1990;
Carr et al, 1995). Whether CDw60 is an activation marker for
keratinocytes and the functional role of this molecule is still unclear,
however, although keratinocyte CDw60 expression may serve as a
costimulatory molecule for T cell activation (ibid). Currently it is also
unknown whether IFN-g and IL-13 signals can mediate biochemical
reactions that impact each other in keratinocytes, or reciprocally
in¯uence cell surface marker expression.
In order to investigate possible antagonistic responses between
Th-1- versus Th-2-type cytokine signals in keratinocytes, we
initially investigated the cell surface marker expression of
keratinocytes upon stimulation with IFN-g versus IL-4 or IL-13,
both alone and in combination. We used a panel of surface markers
consisting of MHC class II (HLA-DR), ICAM-1, and CDw60. To
examine the molecular pathways in keratinocytes for IFN-g, IL-4,
and IL-13, as well as their potential interactions, we also examined
the downstream signaling pathways of these cytokines via STAT1,
STAT6, and BCL-6 transcription factors. IL-4 and IL-13 have been
shown to function through the regulatory protein STAT6 (Palmer-
Crocker et al, 1996). IFN-g has been shown to activate genes
through the transcription factor STAT1. BCL-6 is a known
transcriptional regulator for Th-2-type cytokines. BCL-6 protein is
a nuclear phosphoprotein belonging to the POZ/zinc ®nger family
of transcription factors (Onizuka et al, 1995). Interestingly, BCL-6-
de®cient mice develop a Th-2-type in¯ammation, suggesting that
BCL-6 may be an important regulator of Th-2 response (Dent et al,
1999). Recently, it has been demonstrated that BCL-6 can repress
IL-4-induced transcription mediated by STAT6 (Harris et al, 1999).
Whether IFN-g can alter BCL-6 levels in keratinocyte nuclei,
however, is unknown, and whether BCL-6 plays a role in psoriatic
plaques remains unexplored.
In this report it is demonstrated that IFN-g can completely
inhibit IL-4- or IL-13-mediated induction of CDw60 by
keratinocytes. Moreover, IFN-g can induce both STAT1 and
BCL-6 in cultured keratinocytes, and psoriatic plaques overexpress
the transcriptional repressor BCL-6. Taken together, these
preliminary immunohistochemical results indicated that the lack
of CDw60 expression by keratinocytes in acute psoriatic lesions
may be due to the ability of IFN-g to suppress, via BCL-6, the
IL-4- or IL-13-mediated induction of CDw60. It remains to be
determined exactly how IFN-g blocked surface expression of
CDw60, however, with one possibility being the involvement
of BCL-6 suppressing one or more transcriptional factors that
regulate the complex multistep process in which the acetylated
form of the GD3 ganglioside is expressed by the keratinocyte.
Furthermore, as the chronic plaque evolves, a dynamic interplay
develops between cytokines, their respective signaling pathways,
and transcription factors (Nickoloff, 2000). With this dynamic
system, it can be envisioned that CDw60 expression is induced on
the basal layer, but not above in more super®cial layers, of lesional
keratinocytes. Such reciprocal and antagonistic interactions be-
tween Th-1- and Th-2-type cytokines highlights the complexity of
locally produced cytokines, and suggests that the cytokine network
in acute psoriatic lesions may be different from the cytokine
network in chronic psoriatic plaques.
MATERIALS AND METHODS
Patient samples Four millimeter punch biopsies of normal adult skin,
symptomless psoriatic skin, and active untreated psoriatic plaques were
obtained after local anesthesia and informed consent, using a protocol
approved by the Institutional Review Board. Samples were then snap
frozen in isopentane chilled in liquid nitrogen and stored at ±80°C, or fresh
tissue samples had their proteins extracted for western blot analysis as
described below. Five different normal and psoriatic patients were included
in this study (three female, two male). All psoriatic patients had active
untreated acute (n = 2) or chronic (n = 3) psoriatic lesions.
Human skin/SCID mouse chimera animal model Acute psoriatic
lesions were generated using the human skin/SCID mouse chimera model
as previously described (Nickoloff et al, 1999). Brie¯y, symptomless
psoriatic human skin was orthotopically transplanted onto CB17-SCID
mice. Three weeks following transplantation, bacterially derived
superantigen activated autologous immunocytes (2 3 106) were injected
intradermally into the xenograft. Upon development of an acute psoriatic
lesion at 2 wk, the animal was sacri®ced and a 4 mm punch biopsy was snap
frozen in liquid nitrogen chilled isopentane. Biopsies used in this study
involving SCID mice were obtained during the course of earlier published
experimental protocols (Nickoloff et al, 1999, 2000).
Cell culture Human neonatal foreskin derived keratinocytes were
cultured in keratinocyte growth medium (KGM; Clonetics, San Diego,
CA) containing 0.07 mM Ca2+ as previously described (Stoof et al, 1992).
In some experiments, the KGM was supplemented with additional calcium
to raise the concentration to 2 mM. For cytokine stimulation, keratinocytes
were switched to KGM containing 0.15 mM Ca2+ supplemented with
cytokines as indicated. Based on preliminary studies to determine optimal
concentrations, the actual dosage of cytokines used were as follows: human
recombinant IL-4, 50 ng per ml; human recombinant IL-13, 100 ng per ml;
and IFN-g, 1000 U per ml (all cytokines purchased from R&D Systems,
Minneapolis, MN).
Flow cytometric analysis After 48 h stimulation with different
cytokines, keratinocytes were harvested by using 0.03% trypsin/0.01%
ethylenediamine tetraacetic acid. Then 2 3 105 cells were incubated with
the following antibodies at 4°C for 45 min: 10 mg per ml of phycoerythrin-
conjugated anti-HLA-DR antibody (Becton Dickinson, Sunnyvale, CA);
10 mg per ml of anti-ICAM-1 antibody (Pharmingen, San Diego, CA);
anti-CDw60 antibody UM4D4 ascites was used at 1:400 dilution (generous
gift from Dr. D.A. Fox, University of Michigan, Ann Arbor, MI). Samples
were washed with ¯ow buffer (phosphate-buffered saline, 5% fetal bovine
serum, 0.02% sodium azide) at 4°C for 5 min and centrifuged. After
removing the supernatant, the secondary antibody was added to the cell
pellets and incubated at 4°C for 30 min. Fluorescein-isothiocyanate-labeled
goat antimouse antibody (Biosource International, Camarillo, CA) was
used as the secondary antibody for anti-ICAM-1 antibody and anti-
CDw60 antibody UM4D4. Primary antibody concentrations were
UM4D4 (IgM ascites) diluted 1:100 and BCL-6 rabbit polyclonal (Santa
Cruz Biotechnology, Santa Cruz, CA) diluted 1:25. After incubation, cells
were washed with ¯ow cytometry buffer at 4°C for 5 min and centrifuged.
Cells were ®xed in 2% paraformaldehyde and analyzed with Coulter Epics
XL Flow Cytometer (Miami, FL). To detect intracellular levels of CDw60,
keratinocytes were ®xed with paraformaldehyde and then were
permeabilized using 0.3% saponin (Wrone-Smith et al, 1995), washed,
and processed as described above.
Western blot analysis Nuclear extracts of keratinocytes were prepared
by washing cells with ice-cold phosphate-buffered saline and then
harvesting by scraping from the plates. Buffer A (20 mM HEPES,
pH 7.9, 1.5 mM MgC12, 0.2 mM ethylenediamine tetraacetic acid,
0.5 mM phenylmethylsulfonyl ¯uoride, 0.5 mM dithiothreitol) was added
to the cell pellets, they were incubated on ice for 15 min, and then a 10%
Nonidet P-40 solution was added. After vortexing and centrifugation for
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30 s at 4°C, buffer C [20 mM HEPES, 0.4 M NaCl, 1 mM ethyleneglycol-
bis(b-aminoethyl ether)-N,N,N¢,N¢-tetraacetic acid, 1 mM dithiothreitol,
1 mM phenylmethylsulfonyl ¯uoride] was added to the pellets, and they
were incubated at 4°C for 15 min on a shaking platform. The supernatant
was collected after centrifugation at 4°C in a microfuge for 5 min.
Nuclear protein concentrations were determined by BioRad Assay in
which 30 mg of protein from each sample was loaded onto 8% sodium
dodecyl sulfate polyacrylamide gels, transferred to Immobilon-p (Millipore,
Bedford, MA) membranes, and blocked with 5% nonfat milk in TBST
(50 mM Tris, pH 7.5, 150 mM NaCl, 0.01% Tween 20). Membranes were
incubated with the primary antibody in 2.5% milk in TBST for 2 h and
then washed three times for 10 min each and incubated with 1:1500 diluted
antirabbit horseradish peroxidase (Amersham Pharmacia Biotech,
Piscataway, NJ). Proteins were visualized with ECL reagents (Amersham
Pharmacia Biotech) and exposure to Biomax X-ray ®lm (Kodak,
Rochester, NY). Primary polyclonal rabbit antibodies against STAT1,
phospho-STAT1, STAT6, and BCL-6 (Santa Cruz Biotechnology, Santa
Cruz, CA) and b-actin (Sigma, St. Louis, MO) were used at 10 mg per ml.
Densitometric analysis Radiographic ®lms were scanned with a top lit
HP ScanJet Scanner and analyzed with NIH Image software. Relative
values were determined by integrative average value. The lowest value was
arbitrarily set to 1.0, and higher levels were calculated as fold increases over
this value.
Electrophoretic mobility shift assay In brief, 1 mg of poly-(dI-dC)
(Amersham Pharmacia Biotech) and 105 cpm of 32P-labeled double-
stranded oligonucleotide were incubated with 5 mg of nuclear protein on
ice for 30 min. The reaction mixture was separated on 4% native
polyacrylamide gel, dried, and exposed to ®lm. The STAT1
oligonucleotide has the sequence 5¢-CATGTTATGCATATTCCTGT-
AAGTG-3¢. The STAT6 oligonucleotide has the sequence 5¢-AGA-
TTTCTAGGAATTCAATCC-3¢. The origin of the STAT1 and STAT6
oligonucleotide sequences was derived from Santa Cruz Biotechnology.
Speci®city for these binding assays was con®rmed by use of a speci®c
unlabeled oligonucleotide in a competition analysis for STAT1, and by
performing supershift analysis using antibodies directed against STAT6
(data not shown).
Immunohistochemical staining Cryostat sections were ®xed in cold
acetone and the avidin-biotin peroxidase staining procedure was followed
as previously described (Nickoloff et al, 1995). Brie¯y, primary antibodies
were incubated for 1 h at room temperature followed by subsequent steps as
per the manufacturer's instructions (Vectastain; Vector Laboratories,
Burlingame, CA). Positive detection was accomplished using 3-amino-4-
ethylcarbazole as the chromagen with 1% hematoxylin as the counterstain.
RESULTS
IL-13 treatment of keratinocytes upregulates CDw60
expression and IFN-g pretreatment or simultaneous
treatment blocks induction of CDw60 expression by IL-13
on keratinocytes Previous studies have shown that, in normal
epidermis, basal keratinocytes are negative for CDw60 expression
(Skov et al, 1997). In chronic psoriatic plaques, focal and con¯uent
basal and suprabasal keratinocytes express CDw60 (Skov et al,
1997). The expression of CDw60 is highly variable, however. In
preliminary studies, we observed that the expression pattern of
keratinocyte CDw60 appeared to correlate with the stage
of psoriasis. In the acute phases of psoriasis, there was little to no
CDw60 expression detectable on keratinocytes (data not shown).
In chronic plaques, however, there was more consistent expression
of CDw60 in the basal layer keratinocytes (Fig 1). In searching for a
possible mechanism to explain these different staining patterns, we
were intrigued by the observation from our SCID/human skin
model in which an acute psoriatic-like lesion was created by
injecting a subset of T lymphocytes, the NK T cells (Nickoloff et al,
2000), directly into symptomless skin engrafted on the mouse. In
this study, we also found that, in the acute psoriatic lesion that was
rapidly generated, there was an absence of CDw60 expression by
the epidermal keratinocytes (Fig 1). Probing this acute lesion, we
observed that there were elevated levels of the Th-1-type cytokine
(i.e., IFN-g) mRNA and low to absent Th-2-type cytokines (e.g.,
absent IL-4 and low IL-13 mRNA production) (Nickoloff et al,
2000). As it has been shown that IL-4 and IL-13 upregulate the
surface expression of CDw60 on keratinocytes, whereas IFN-g
decreases its constitutive expression (Skov et al, 1997), this led us to
speculate that the expression of CDw60 by keratinocytes may be
modulated by an antagonistic interaction involving Th-1- versus
Th-2-type cytokines.
In order to explore the cell surface expression of the acetylated
ganglioside GD3 (i.e., CDw60) and its regulation, normal
keratinocytes were stimulated with different cytokines, and
CDw60 surface expression was examined by ¯ow cytometric
analysis. Cells were maintained in a proliferative state at low
density, and stimulated for 48 h before harvesting and staining. As
shown in Fig 2(A), normal cultured keratinocytes grown in low
calcium (0.07 mM) KGM express a relatively low level of CDw60
constitutively on a minority of cells (30%). When grown in KGM
supplemented with an elevated level of Ca2+ (2.0 mM), however, a
greater number of keratinocytes (54%) express higher levels of
CDw60 (Fig 2B), whereas other surface molecules such as MHC
class I, class II molecules and adhesion molecules remain unaltered
(data not shown). Furthermore, stimulation of keratinocytes with
IL-13 for 48 h produces a 2±3 log shift of the surface expression of
CDw60 by almost all of the cells (97%) (Fig 2C). Although IL-13
can cause a signi®cant upregulation of CDw60 expression, other
cell surface markers remained unchanged, namely ICAM-1, MHC
class I, and MHC class II molecules (HLA-DR) (data not shown).
IFN-g is a type 1 cytokine with biologic functions antagonistic to
the type 2 cytokines in many cellular systems. The effect of IFN-g
on keratinocytes with regard to CDw60 expression, however, has
not been thoroughly investigated. In our in vitro system, we
demonstrate that treatment of keratinocytes with IFN-g failed to
induce CDw60 expression; on the contrary, we con®rmed an
earlier report in which IFN-g could suppress constitutively low
expression (Fig 2D). Moreover, IFN-g can antagonize the effect of
IL-13 on keratinocytes by inhibiting the upregulation of CDw60
expression. This has been demonstrated by either pretreating
keratinocytes with IFN-g for 6 h before incubating with IL-13 for
48 h, or treating the cells with both IFN-g and IL-13 simulta-
neously for 48 h (Fig 2E, H, respectively).
IFN-g alone can induce MHC class I, MHC class II, and the
adhesion molecule ICAM-1 protein expression by keratinocytes
(data not shown). Moreover, in the presence of both IFN-g and IL-
13, the induction of some IFN-g inducible genes such as HLA-DR
and ICAM-1 is still prominent (Figs 1F, G, I, J). Thus, IFN-g can
inhibit IL-13-induced CDw60 expression on keratinocytes, but
IL-13 has no reciprocal inhibition on the expression of IFN-g-
induced genes.
IL-4 is a type 2 cytokine that shares many functional similarities
to IL-13. When keratinocytes were treated with IL-4 for 48 h,
similar results regarding the upregulation of CDw60 expression as
the IL-13 treatment were obtained. Moreover, pretreatment or
simultaneous treatment with IL-4 at the same time as IFN-g
treatment does not block the keratinocytes from down-modulating
their CDw60 expression in response to the IFN-g (data not
shown).
To determine if IFN-g was preventing IL-4 or IL-13 upregula-
tion of CDw60 secondary to inhibition of intracellular levels,
keratinocytes were permeabilized and then examined by ¯ow
cytometry. Figure 3 reveals that there are constitutive intracellular
levels of CDw60 in keratinocytes, but that IFN-g does not inhibit
these intracellular levels, despite the complete blockage of IL-4
induction of cell surface CDw60 expression. Given the known
complexity in the biochemical pathway required for synthesis of
the acetylated form of the ganglioside GM3, including transport
from intracellular to extracellular sites, we decided to initially focus
on transcriptional events that may impact various signaling
pathways that could also in¯uence CDw60 expression.
Induction of STAT1 nuclear protein by IFN-g In order to
characterize the biochemical pathways utilized by IFN-g or IL-4/
IL-13, and especially to elucidate the mechanism responsible for the
IFN-g-mediated inhibition of keratinocyte CDw60 expression
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mediated by IL-13, we investigated downstream signaling events. It
has been shown in other cellular systems that IFN-g can signal via
STAT1 (Tessitore et al, 1998; Piskurich et al, 1999). Upon
activation, STAT1 becomes phosphorylated, forms a dimer and
translocates into the nucleus, and then binds to the STAT1-speci®c
site in the promoter region, inducing IFN-g-responsive genes. As
keratinocytes still respond to IFN-g even in the presence of Th-2
cytokines (Fig 2), we initially explored STAT1 signaling in
keratinocytes.
In proliferating keratinocytes, a basal level of STAT1 is
detectable in the nucleus (Fig 4A). Upon IFN-g stimulation (103
U per ml, 1 h), there is a signi®cant induction of STAT1
translocation to the nucleus (Fig 4A). Accumulation of STAT1
in the nucleus peaks at 1 h poststimulation, and then decreases but
Figure 1. Immunohistochemical staining for
CDw60 expression in acute and chronic
psoriatic plaques. (A) An acute psoriatic lesion
generated using the SCID/human skin model re-
veals no detectable CDw60 staining on keratino-
cytes, but some on mononuclear cells in the
dermis. Note the typical histologic appearance for
a psoriatic lesion including parakeratosis, loss of
the granular cell layer, and elongated rete pegs.
(B) A chronic psoriatic plaque with overexpression
of CDw60 primarily con®ned to the basal and
lower epidermal layers of keratinocytes, but absent
from almost all suprabasal layer keratinocytes.
Figure 2. Analysis of the cell surface expression of CDw60, HLA-DR, and ICAM-1 on normal cultured keratinocytes by ¯ow cytometry. (A±
E, H) CDw60; (F, I) HLA-DR; (G, I) ICAM-1. Whereas only rare keratinocytes constitutively express CDw60 in low calcium (0.07 mM) medium (A),
raising the extracellular calcium to 2.0 mM levels enhanced the number and intensity of CDw60 by keratinocytes (B). Addition of IL-13 (100 ng per ml,
48 h) triggers signi®cantly greater CDw60 expression (C), but IFN-g inhibits all constitutive CDw60 expression (D). Keratinocytes pretreated with IFN-g
(1000 U per ml, 6 h) followed by continuous exposure to IL-13 results in no keratinocyte CDw60 expression (E), nor does simultaneous addition of both IL-
13 and IFN-g (H). Induction of keratinocyte expression of HLA-DR by IFN-g is not in¯uenced by the presence of IL-13 (F, I). Induction of keratinocyte
expression of ICAM-1 by IFN-g is also not in¯uenced by the presence of IL-13 (G, I).
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can still be detected at 4 h. There is no detectable induction of
STAT1 translocation upon IL-13 stimulation. Interestingly, when
keratinocytes are exposed to simultaneous stimulation with both
IFN-g and IL-13, there is still induction of STAT1. This suggests
that, even though both cytokines IFN-g and IL-13 are present,
IFN-g signaling via STAT1 proceeds unaffected by the Th-2
cytokine.
In order to con®rm that the STAT1 accumulation is due to
signaling events such as phosphorylation and translocation into the
nuclei, we used a monoclonal antibody that recognizes only the
phosphorylated form of STAT1. As demonstrated by the western
blot analysis of phospho-STAT1 level (Fig 4B), untreated
proliferating keratinocytes, as well as IL-13-stimulated keratino-
cytes (1 h or 4 h after stimulation), do not show any detectable level
of phospho-STAT1. Signi®cant induction of phospho-STAT1
level was detected upon IFN-g stimulation at 1 h, however. This
phospho-STAT1 level was still detectable after 4 h stimulation,
though at a reduced level. For keratinocytes that were stimulated
with IFN-g and IL-13 simultaneously, similar results to IFN-g
alone at the same time points were observed, again indicating that
when both IFN-g and IL-13 are present the IFN-g signaling
pathway through STAT1 is functional.
Induction of STAT6 by IL-13 stimulation In order to
determine the IL-13 signaling pathway in keratinocytes, STAT6
phosphorylation and DNA binding activity were analyzed. As shown
in Fig 5, the level of STAT6 in untreated keratinocytes is barely
detectable, as is the STAT6 level in keratinocytes stimulated with
IFN-g for 1 h. IL-13 exposure of keratinocytes for 1 h increases the
nuclear STAT6 levels signi®cantly, however, although the STAT6
levels after 4 h of IL-13 stimulation subsides. Interestingly, for
keratinocytes that underwent treatment with both IFN-g and IL-13,
comparable levels of induction of STAT6 as IL-13 alone were
observed. This indicates that, even though IFN-g is present, STAT6
translocation to the nucleus can still occur, suggesting that IL-13
signaling blockage by IFN-g is downstream of STAT6 translocation.
Increased DNA binding activity of STAT1 protein in
keratinocytes after IFN-g stimulation Because there is an
increased level of STAT1 protein in the nuclei of keratinocytes
upon IFN-g stimulation, including phospho-STAT1, we next
examined if STAT1 from cultured keratinocytes can actually bind
to the promoter region of an IFN-g gene element. As shown in
Fig 6, in proliferating keratinocytes there is no detectable binding
activity of the transcription factor to a STAT1-speci®c labeled
oligo, but binding increases upon IFN-g stimulation as shown at
both 30 min and 60 min poststimulation.
Figure 3. Determination of intracellular and
cell surface levels of CDw60 in keratinocytes,
before and after exposure to cytokines. Intra-
cellular levels were measured by permeabilizing
cells using 0.3% saponin (right side panel), whereas
cell surface levels were assessed without permeabi-
lization (left side panels). Keratinocytes maintained
in 0.15 mM Ca2+-containing KGM constitutively
express low surface levels of CDw60 as well as in-
tracellular levels compared with isotype control
staining (open curves). IL-4 (48 h) increases surface
expression of CDw60 but does not alter intracel-
lular levels. IFN-g (48 h) does not in¯uence either
intracellular or extracellular levels of CDw60. Ad-
dition of IFN-g plus IL-4 inhibits induction of
surface levels of CDw60, but has no effect on in-
tracellular amounts of CDw60 in cultured kerati-
nocytes.
Figure 4. Western blot analysis of transcription factors STAT1 and
phosphorylated STAT1 in the nuclei of keratinocytes before and
after cytokine stimulation. STAT1 is a heterodimer consisting of a 91
kDa and an 84 kDa protein complex. Phosphorylated STAT1 protein
detected with a phosphorylation-speci®c antibody to the phosphorylated
91 kDa subunit. (A) Constitutive level of STAT1 in the nuclei of
proliferating keratinocytes. (B) The level of phosphorylated STAT1. Lane
1, proliferating keratinocytes; lane 2, keratinocytes following IFN-g
treatment for 1 h; lane 3, keratinocytes treated with IL-13 for 1 h; lane 4,
keratinocytes stimulated with IFN-g and IL-13 simultaneously for 1 h; lane
5, keratinocytes stimulated with IFN-g for 4 h; lane 6, keratinocytes
stimulated with IL-13 for 4 h; lane 7, keratinocytes stimulated simulta-
neously with IFN-g and IL-13 for 4 h. b-actin levels are used as a control to
verify equal protein loading of the lanes.
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Induction of increased BCL-6 levels in the nucleus of
keratinocytes after IFN-g stimulation In order to investigate
the possible mechanisms of the differential effects of the various
cytokines on keratinocyte expression of the acetylated form of the
GM3 ganglioside (i.e., CDw60), we examined a downstream
signaling pathway, focusing on the intranuclear level of BCL-6 in
keratinocytes.
The BCL-6 protein is a nuclear phosphoprotein belonging to the
POZ/zinc ®nger family of transcription factors. Interestingly,
BCL-6-de®cient mice develop a Th-2-type in¯ammation, suggest-
ing that BCL-6 may be an important regulator of Th-2 response.
Recently, it has been demonstrated that BCL-6 can repress IL-4-
induced transcription mediated by STAT6 (Harris et al, 1999).
Whether IFN-g can in¯uence the levels of BCL-6 in the
keratinocyte nucleus, however, was not previously known.
Normal keratinocytes were stimulated with cytokines IFN-g,
IL-4, or IL-13 for 4 h. In addition, cells were also pretreated with
either IFN-g or IL-4 for 1 h before the addition of a second
cytokine, IL-4 for IFN-g and IFN-g for IL-4, for an additional 4 h.
As shown in Fig 7, proliferating keratinocytes have constitutive
nuclear BCL-6 levels detectable by western blot analysis (panel A);
however, treatment with IFN-g can increase the BCL-6 level
signi®cantly, whereas IL-4 (IL-13, data not shown) treatment had
no effect on the BCL-6 level. Moreover, these results also indicate
that IFN-g is a strong inducer of BCL-6, as pretreatment of
keratinocytes with IL-4 (or IL-13, data not shown) could not
prevent the BCL-6 induction by IFN-g. These results indicate that
IFN-g can induce increased nuclear levels of the transcriptional
repressor BCL-6, and this induction is not affected by these
Th-2-type cytokines (i.e., IL-4 or IL-13).
Distribution pattern and overexpression of BCL-6 in normal
and psoriatic skin To determine if these in vitro results could be
relevant to the in vivo setting, skin biopsies were examined for
BCL-6 expression. By immunohistochemistry, intranuclear
expression of BCL-6 can be detected in keratinocytes in psoriatic
plaques, but not in symptomless psoriatic skin (Fig 7B). Within
psoriatic skin, there were differences in the pattern of expression of
BCL-6 depending on the stage of the lesion. In the acute lesion
there was more prominent localization in the basal cell layer,
whereas in chronic plaques the nuclear BCL-6 appears
predominantly in the suprabasal layers of keratinocytes (Figs 7B3,
7B4). This preliminary determination of BCL-6 overexpression in
psoriatic plaques was con®rmed by western blot analysis (Fig 7C).
In normal tissue from healthy individuals (NN skin, lanes 1, 2), and
symptomless skin from a psoriatic patient (PN skin, lane 3), low
levels of BCL-6 expression were detected. In psoriatic plaques (PP
skin, lanes 4, 5), however, enhanced expression of BCL-6 levels can
be observed. By densitometry, this overexpression in psoriatic
Figure 5. Western blot analysis of transcription factor STAT6 in the
nuclei of keratinocytes upon cytokine stimulation. STAT6 has a
molecular weight of 110 kDa. Lane 1, proliferating keratinocytes; lane 2,
keratinocytes treated with IFN-g for 1 h; lane 3, keratinocytes treated with
IL-13 for 1 h; lane 4, keratinocytes stimulated with IFN-g and IL-13
simultaneously for 1 h; lane 5, keratinocytes stimulated with IL-13 for 1 h;
lane 6, keratinocytes stimulated with IFN-g and IL-13 simultaneously for
4 h. b-actin levels are used as a control to verify the equal protein loading of
the lanes.
Figure 6. Mobility shift assay of STAT1 protein in keratinocytes
stimulated with IFN-g. Lane 1, unstimulated keratinocytes; lane 2,
keratinocytes treated with IFN-g (103 U per ml) for 30 min; lane 3,
keratinocytes treated with IFN-g (103 U per ml) for 1 h. Note the induction
of binding of STAT1 protein for its DNA target sequence following
treatment with IFN-g at 30 min and 1 h.
Figure 7. Western blot analysis of BCL-6 level in the nuclei of
normal cultured keratinocytes. (A) Induction of BCL-6 in the nuclei
of keratinocytes by IFN-g. Lane 1, proliferating keratinocytes; lane 2,
keratinocytes stimulated with IFN-g for 4 h; lane 3, keratinocytes stimulated
with IL-4 for 4 h; lane 4, keratinocytes pretreated with IFN-g for 1 h
followed by the addition of IL-4 for 4 h; lane 5, keratinocytes pretreated
with IL-4 for 1 h followed by the addition of IFN-g for 4 h. (B)
Immunohistochemical analysis of BCL-6 in the nuclei of keratinocytes in
normal skin (NN, B1), symptomless prepsoriatic skin (PN, B2), acute
psoriatic lesion (B3), and chronic psoriatic lesion (B4). Note the absence of
BCL-6 staining in NN and PN skin, but the BCL-6 positive staining and
nuclear localization is con®ned primarily to basal layer keratinocytes in
acute lesions (panel B3, open arrows). In contrast, in chronic psoriatic plaques
(PP, panel B4), BCL-6 intranuclear staining is predominantly seen on
suprabasal layer keratinocytes (closed arrows) (C) Western blot analysis of
BCL-6 levels present in protein extracts from NN skin (lanes 1, 2), PN skin
(lane 3), PP skin (lanes 4±6). Note the enhanced levels of BCL-6 in psoriatic
lesions. b-actin levels are used as a control to verify equal protein loading of
the lanes.
310 HUANG ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
lesions ranged from 2.9- to 8.8-fold compared with symptomless
skin.
DISCUSSION
Although it has been established that activated T cells can trigger
the onset of psoriatic lesions, the precise biochemical pathways and
transcriptional regulators mediating this phenotypic conversion are
largely unknown (Valdimarsson et al, 1986; Schlaak et al, 1994;
Gottlieb et al, 1995; Boehncke et al, 1996; Gilhar et al, 1997;
Yamamoto et al, 1998; Nickoloff, 1999). Furthermore, whereas
individual cytokines are often the focus of in vitro studies dealing
with the interactions between T cells and keratinocytes, the actual
disease state represents a mixture of multiple cytokines that produce
a so-called cytokine network (Nickoloff, 1991). Even though
psoriatic plaques contain an abundance of Th-1-type cytokines
such as IFN-g, the pathologic role for Th-2-type cytokines is
generally disregarded, although some investigators have begun
using cytokines such as IL-10 to treat psoriatic patients (Uyemura
et al, 1993; Nickoloff et al, 1994; Asadullah et al, 1999). In this
report, we investigated the complex interactions by which a Th-1-
type cytokine (i.e., IFN-g) could antagonize two different Th-2-
type cytokines (IL-4 and IL-13), with regard to keratinocyte
expression of CDw60.
CDw60 was selected for this study because it has been implicated
in mediating T cell activation in psoriasis, and because its variable
pattern of expression in lesional skin suggested a dynamic level of
regulation (Skov et al, 1997). As CDw60 represents an acetylated
form of the GD3 ganglioside, however, rather than a protein, it is
likely that many enzymes and biochemical pathways are involved in
its ultimate cell surface expression. This presents several challenges
to elucidate molecular events that contribute to the surface
expression of CDw60 (Paller et al, 1993; 1995). Nonetheless, we
attempted to begin probing potentially important pathways both at
the cytokine level and the transcriptional level. The current results
extend these earlier ®ndings by demonstrating that IFN-g can
completely block the ability of either IL-4 or IL-13 to induce
CDw60 expression in cultured keratinocytes. Such a molecular
based antagonistic effect by which IFN-g suppressed IL-4/IL-13
induction of CDw60 parallels the cellular immune reaction in
which the Th-1-type and Th-2-type T cells are observed to be
mutually antagonistic and self-reinforcing (Kroemer et al, 1996). To
begin to elucidate the mechanism by which IFN-g could suppress
IL-4/IL-13 induction of keratinocyte CDw60, several different
studies were performed. First, it was demonstrated that, whereas
IFN-g antagonizes the biologic effects of IL-4/IL-13, there was no
reciprocal reaction, as neither IL-4 nor IL-13 could inhibit the
ability of IFN-g to induce either HLA-DR or ICAM-1.
Second, as no previous study had addressed the potential
crosstalk amongst transcription factors mediating these cytokine
effects, we determined the patterns of expression for several key
transcription factors in keratinocytes. It was observed that IL-4/
IL-13 could induce STAT6 but not STAT1, whereas IFN-g
induced STAT1 and not STAT6. As IFN-g could not block the IL-
4/IL-13 mediated activation of STAT6, we explored a more distal
signaling pathway involving the transcription repressor BCL-6. As
shown in Fig 7, IFN-g was documented to induce BCL-6
intranuclear levels in the keratinocytes. Moving from the in vitro
studies, it became clear that, whereas normal or symptomless skin
had low to nondetectable levels of BCL-6 by western blot analysis
and immunostaining assays, there was overexpression of BCL-6 in
psoriatic plaques. Moreover, the pattern of intranuclear BCL-6-
positive keratinocytes was inversely correlated to the CDw60
expression in these preliminary ®ndings. Thus in acute psoriatic
plaques, high intranuclear BCL-6 levels were detected in basal layer
keratinocytes in which there was no CDw60 expression, whereas
in chronic plaques, the keratinocytes in the suprabasal layers that
had high levels of BCL-6 failed to express CDw60. Taken together,
these in vitro and in vivo studies suggest that the transcriptional
repressor BCL-6 modulates the keratinocyte CDw60 expression.
Obviously, considerable work is required to extend these
preliminary ®ndings to more precisely determine which transcrip-
tion factors modulate CDw60 expression, and whether such
transcription factors can be directly or indirectly suppressed by
BCL-6.
Finally, these studies support the notion that psoriasis arises as a
consequence of complex cellular and molecular interactions
involving cytokines produced by various T cell subsets. Whereas
it is generally appreciated that IFN-g can function to trigger the
appearance of many important immunologically relevant molecules
such as HLA-DR and ICAM-1, it is now clear that IFN-g can also
have antagonistic biologic effects. One recent report documented
the failure of IFN-g-treated epithelial cells to stimulate proliferation
of CD4+ T cells, whereas the same cells transfected with a full-
length MHC class II transactivation gene did promote T cell
proliferation (Lawson et al, 2000). These results, together with our
data, highlight the many unresolved issues still surrounding the
complexities underlying T cell-keratinocyte interactions, and the
biochemical basis responsible for the modulation of expression of
critically important immunologically active surface molecules.
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